Abstract
Immunization against the spike protein of SARS-CoV-2 reduces transmission 1,2 and severe outcomes. However, little is known regarding the impact of immune-mediated diseases and immunosuppressive medications on the efficacy of vaccination. Vaccination immunity is transient, with breakthrough cases increasing at longer time intervals since the last dose. 3,4 Although there are data on SARS-CoV-2 vaccine on early seroconversion in patients with inflammatory bowel disease (IBD), 5 no data in the same cohort exist describing the durability of these antibodies over time. We sought to investigate the impact of IBD and its therapies on postvaccination antibody response and kinetics of immunogenicity decline, because these findings may better inform clinical guidelines and recommendations on precautions and booster vaccination.
【초록키워드】 SARS-CoV-2, Efficacy, vaccination, therapy, Immunity, antibody, Antibody Response, Transmission, SARS-CoV-2 vaccine, Inflammatory bowel disease, outcomes, Cohort, Seroconversion, Patient, Precaution, IBD, booster vaccination, dose, time interval, postvaccination, Immunosuppressive medication, recommendation, clinical guideline, immune-mediated disease, the spike protein, reduce, 【제목키워드】 SARS-CoV-2, response, Impact,